Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Colorcon
McKinsey
McKesson
Boehringer Ingelheim

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Gossypol

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Gossypol?

Gossypol is an investigational drug.

There have been 10 clinical trials for Gossypol. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.

The most common disease conditions in clinical trials are Lung Neoplasms, Small Cell Lung Carcinoma, and Leukemia, Lymphocytic, Chronic, B-Cell. The leading clinical trial sponsors are National Cancer Institute (NCI), Mayo Clinic, and Third Military Medical University.

There are seven hundred and eighty-three US patents protecting this investigational drug and four international patents.

Recent Clinical Trials for Gossypol
TitleSponsorPhase
R-(-)-Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple MyelomaNational Cancer Institute (NCI)Phase 1/Phase 2
R-(-)-Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple MyelomaMayo ClinicPhase 1/Phase 2
Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic LeukemiaNational Cancer Institute (NCI)Phase 1/Phase 2

See all Gossypol clinical trials

Clinical Trial Summary for Gossypol

Top disease conditions for Gossypol
Top clinical trial sponsors for Gossypol

See all Gossypol clinical trials

US Patents for Gossypol

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Gossypol   Start Trial Heterocyclic compounds useful in the treatment of disease Epigen Biosciences, Inc. (San Diego, CA)   Start Trial
Gossypol   Start Trial Pyrazol-3-ones that activate pro-apoptotic BAX Dana-Farber Cancer Institute, Inc. (Boston, MA)   Start Trial
Gossypol   Start Trial Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders Dana-Farber Cancer Institute, Inc. (Boston, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Express Scripts
Moodys
Dow
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.